BIOHIT HealthCare to host webinar exploring current and future trends in TDM for IBD management

June 26, 2024

BIOHIT HealthCare is excited to announce an upcoming webinar on the Current and future trends in inflammatory bowel disease (IBD) therapeutic drug monitoring (TDM), which will take place on the 3rd of July at 12:30-1:30pm BST. The BIOHIT team will be joined by Rachel Nice, Section Lead for R&D and Specialist Services at Exeter Clinical Laboratory, and Rebecca Smith, Gastroenterology Specialist Registrar, both from the Royal Devon University Healthcare NHS Foundation Trust, to tackle the burning questions around this topical subject.

The management of IBD is rapidly evolving, driven by recent studies and advances, including the personalized anti-TNF therapy in Crohn’s disease (PANTS study). In this webinar, the expert speakers will explore various topics surrounding TDM, including our current understanding, the development of immunogenicity and importance of early optimisation, as well as how we can use TDM most effectively to enable subcutaneous drug delivery and manage biologics treatment in the first year of therapy. They will also delve into applications beyond anti-TNF therapies, and discuss how this approach may be used alongside pharmaco-multiomics in the future.

This event is an excellent opportunity to gain insights from leading experts in the field, ask questions, and join in the conversation about the future of IBD management with TDM. BIOHIT welcomes healthcare professionals, researchers and anyone interested in the evolving management of IBD to register for this free event.

Register now.


About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk

Recent Posts

Reinventing BAD diagnosis with fast, non-invasive testing

May 2, 2025

Point-of-care testing for atrophic gastritis can help relieve the pressure on endoscopy services

March 31, 2025

Improving gastric cancer outcomes through earlier diagnosis

March 7, 2025

Closing the quality gap with Helicobacter pylori Control+ for rapid urease tests

March 5, 2025